HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies Antares Therapeutics, Inc. a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop…
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Definium Therapeutics, Inc. a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Pfizer Inc. announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential…
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch…
Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together…
101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease 101 Therapeutics Ltd. today announced the public release of its clinical and scientific evidence package for 101-PGC-005 (‘005), a macrophage-targeted dexamethasone prodrug…
Gurobi’s Research Leadership Recognized Across Leading Scientific Organizations Gurobi Optimization, LLC, the leader in decision intelligence technology, announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting…
OKI Selected as Representative Organization for JAXA Space Strategy Fund Project Proposed Jointly with LTS OKI has been selected as the representative organization for the technology development project titled “Development and Global Deployment of a Next-Generation Infrastructure Monitoring System Through…
insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions insitro, the physical AI company unlocking causal human biology, presented new preclinical data from its metabolic dysfunction-associated…
CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026 CicadaBio announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at…